Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Clinical trial NCT06770842 · RECRUITING

Trial details

NCT number: NCT06770842
Sponsor: The University of Hong Kong
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Start date: 2025-03-01
Primary completion: 2026-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.